Background Large-scale vaccination against COVID-19 is being implemented in many countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune persistence of a two-dose schedule of CoronaVac, and the immunogenicity and safety of a third dose of CoronaVac, in healthy adults aged 18 years and older. Methods In the first of two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, adults aged 18-59 years in Jiangsu, China, were initially allocated (1:1) into two vaccination schedule cohorts: a day 0 and day 14 vaccination cohort (cohort 1) and a day 0 and day 28 vaccination cohort (cohort 2); each cohort was randomly assigned (2:2:1) to either a 3 mu g dose or 6 mu g dose of CoronaVac or a placebo group. Following a protocol amendment on Dec 25, 2020, half of the participants in each cohort were allocated to receive an additional dose 28 days (window period 30 days) after the second dose, and the other half were allocated to receive a third dose 6 months (window period 60 days) after the second dose. In the other phase 2 trial, in Hebei, China, participants aged 60 years and older were assigned sequentially to receive three injections of either 1.5 mu g, 3 mu g, or 6 mu g of vaccine or placebo, administered 28 days apart for the first two doses and 6 months (window period 90 days) apart for doses two and three. The main outcomes of the study were geometric mean titres (GMTs), geometric mean increases (GMIs), and seropositivity of neutralising antibody to SARS-CoV-2 (virus strain SARS- CoV-2/human/CHN/CN1/2020, GenBank accession number MT407649.1), as analysed in the per- protocol population (all participants who completed their assigned third dose). Our reporting is focused on the 3 mu g groups, since 3 mu g is the licensed formulation. The trials are registered with ClinicalTrials.gov, NCT04352608 and NCT04383574. Findings 540 (90%) of 600 participants aged 18-59 years were eligible to receive a third dose, of whom 269 (50%) received the primary third dose 2 months after the second dose (cohorts 1a-14d-2m and 2a-28d-2m) and 271 (50%) received a booster dose 8 months after the second dose (cohorts 1b-14d-8m and 2b-28d-8m). In the 3 mu g group, neutralising antibody titres induced by the first two doses declined after 6 months to near or below the seropositive cutoff (GMT of 8) for cohort 1b-14d-8m (n=53; GMT 3.9 [95% CI 3.1-5.0]) and for cohort 2b-28d-8m (n=49; 6.8 [5.2-8.8]). When a booster dose was given 8 months after a second dose, GMTs assessed 14 days later increased to 137.9 (95% CI 99.9-190.4) for cohort 1b-14d-8m and 143.1 (110.8-184.7) 28 days later for cohort 2b-28d-8m. GMTs moderately increased following a primary third dose, from 21.8 (95% CI 17.3-27.6) on day 28 after the second dose to 45.8 (35.7-58.9) on day 28 after the third dose in cohort 1a-14d-2m (n=54), and from 38.1 (28.4-51.1) to 49.7 (39.9-61.9) in cohort 2a-28d-2m (n=53). GMTs had decayed to near the positive threshold by 6 months after the third dose: GMT 9.2 (95% CI 7.1-12.0) in cohort 1a-14d-2m and 10.0 (7.3-13.7) in cohort 2a-28d-2m. Similarly, in adults aged 60 years and older who received booster doses (303 [87%] of 350 participants were eligible to receive a third dose), neutralising antibody titres had declined to near or below the seropositive threshold by 6 months after the primary two-dose series. A third dose given 8 months after the second dose significantly increased neutralising antibody concentrations: GMTs increased from 42.9 (95% CI 31.0-59.4) on day 28 after the second dose to 158.5 (96.6-259.2) on day 28 following the third dose (n=29). All adverse reactions reported within 28 days after a third dose were of grade 1 or 2 severity in all vaccination cohorts. There were three serious adverse events (2%) reported by the 150 participants in cohort 1a-14d-2m, four (3%) by 150 participants from cohort 1b-14d-8m, one (1%) by 150 participants in each of cohorts 2a-28d-2m and 2b-28d-8m, and 24 (7%) by 349 participants from cohort 3-28d-8m. Interpretation A third dose of CoronaVac in adults administered 8 months after a second dose effectively recalled specific immune responses to SARS-CoV-2, which had declined substantially 6 months after two doses of CoronaVac, resulting in a remarkable increase in the concentration of antibodies and indicating that a two-dose schedule generates good immune memory, and a primary third dose given 2 months after the second dose induced slightly higher antibody titres than the primary two doses. Copyright (C) 2021 Published by Elsevier Ltd. All rights reserved.

Background: The purpose of our study was to determine the persistence of CoronaVac vaccine-induced immunity from a primary three-dose regimen and a primary two-dose plus one booster dose given after an 8-month interval regimen in adults aged 18 years and older. Methods: In the first of two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials, adults aged 18-59 years in Jiangsu, China, were allocated (1:1:1:1) into four vaccination schedule cohorts: cohort 1a-14d-2m, cohort 1b-14d-8m, cohort 2a-28d-2m, and cohort 2b-28d-8m, with 14d and 28d representing the interval in days between the first two doses, and 2m and 8m denoting the actual median interval in months between the second and third doses. Each cohort was randomly assigned (2:2:1) to receive either a 3 μg dose or a 6 μg dose of CoronaVac or a placebo. In the other phase 2 trial, conducted in Hebei, China, participants aged 60 years and older were assigned sequentially to receive three injections of either 1.5 μg, 3 μg, or 6 μg of vaccine or a placebo, administered 28 days apart for the first two doses and 8 months later for dose three. The primary outcomes of the study were geometric mean titres (GMTs) and seropositivity of neutralising antibody to SARS-CoV-2 (virus strain SARS-CoV-2/human/CHN/CN1/2020, GenBank accession number MT407649.1), as analysed in the per-protocol population (all participants who received their assigned doses). Our reporting is focused on the 3 μg groups in cohort 2b-28d-8m and cohort 3-28d-8m, since 3 μg is the licensed formulation and an additional (third) dose is recommended at a 6-month interval after the second primary dose. The trials are registered with ClinicalTrials.gov, NCT04352608 and NCT04383574. Findings: In adults aged 18-59 years of age, 268 (89%) of 300 participants completed a 1-year follow up after their primary three-dose series (cohort 1a-14d-2m and cohort 2a-28d-2m), and 259 (86%) of a different 300 participants completed their 6-month follow up after receiving booster doses (cohort 1b-14d-8m and cohort 2b-28d-8m). In the 3 μg groups, neutralising antibody titres induced by booster doses declined approximately 4-fold after 6 months for cohort 1b-14d-8m (GMT from 137.9 [95%CI 99.9-190.4]) to 33.4 [95% CI 25.0-44.6]) and cohort 2b-28d-8m (GMT from 143.3 [95%CI 112.3-182.8]) to 36.4 [95% CI 28.7-46.1]). GMTs decreased 5-fold after 6 months and remained stable between 6 months and 1 year following a primary third dose, from 45·8 (95% CI 35.7-58.9) on day 28 to 9.2 (95%CI 7.1-12.0) on day 180 and 8.3 (95%CI 6.1-11.3) 1 year after the third dose in cohort 1a-14d-2m, and from 49.7 (95%CI 39.9-61.9) to 10.0 (95%CI 7.3-13.7) and to 10.7 (95%CI 7.6-15.1) in cohort 2a-28d-2m. Similarly, in adults aged 60 years and older, GMTs declined from 158.5 (95%CI 96.6-259.2) on day 28 to 53.2 (95%CI 39.7-71.1) on day 180 following the booster dose in the 3 μg group, a 2.5-fold decrease. There was one serious adverse event (1%) reported among the 259 participants in cohort 1b-14d-8m and cohort 2b-28d-8m, and fourteen (5%) among the 303 participants in cohort 3-28d-8m during the 6 months after booster dose administration. Interpretation: There were increases in the magnitude and duration of neutralization and improvement in the kinetics of the humoral response with homologous booster doses of CoronaVac given 8 months after a primary two-dose immunization series, which could prolong protection and contribute to building our wall of population immunity.Clinical Trial Registration Details: The two trials were registered with ClinicalTrials.gov, NCT04352608 and NCT04383574.Funding Information: The study was supported by grants from National Key Research and Development Program (2020YFC0849600), Beijing Science and Technology Program (Z201100005420023), and Key Program of the National Natural Science Foundation of China (82130093).Declaration of Interests: H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. None of those research funding is related to development of COVID-19 vaccines. Q.X. and T.Y. were the employees of Sinovac Biotech Ltd., L.W. was the employee of Sinovac Life Sciences Co., Ltd. All other authors report no competing interests.Ethics Approval Statement: The complete study protocol for adults aged 18-59 years old was approved by the ethics committees of Jiangsu Provincial Centre for Disease Control and Prevention (JSJK2020-A021–02), and the complete study protocol for adults aged 60 years and older was approved by the ethics committees of Hebei Provincial Centre for Disease Control and Prevention (IRB2020–006). All participants gave written informed consent to participate in the study before administration of first doses and booster doses.

Although recognized as a curable disease, the persistence of hepatitis C virus (HCV) in chronically infected patients remains a great burden for public health. T cell immune responses serve a key role in anti-HCV infection; however, the features of T cell immunity in patients after a long-term infection are not well explored. We recruited a special cohort of patients with similar genetic background and natural developing progression of disease who were infected with HCV through blood donation 35 y ago. We found that self-resolved individuals had higher levels of cytokine-secreting T cells than individuals with chronic infections, indicating HCV-specific T cell immunity could be sustained for >35 y. Meanwhile, virus-specific CD8+ T cells in chronic patients were characterized by programmed cell death-1high, TIM-3high expression, which was related to liver injury characterized by aspartate transaminase/alanine aminotransferase levels and morphopathological changes. Unexpectedly, the expression of Lymphocyte-activation gene 3 on CD8+ T cells was lower in chronic patients and negatively correlated with alanine aminotransferase/aspartate transaminase. Our findings provided new insights into HCV-specific T cell responses and may shed light on a way to figure out novel effector targets and explore a way to reverse chronic infections.

Objective:To understand the situation of hepatitis B booster vaccination in population and its influencing factors, so as to provide reference for hepatitis B booster immunization.Methods:The study was conducted in Zhengding county which was the monitoring site for observing the immune effect of hepatitis B vaccine and Dingxing county. Participants who were born from 1986 to 2011 and had completed hepatitis B primary vaccination were enrolled. A questionnaire survey was carried out among the participants to analyze the situation of hepatitis B booster immunization. Logistic regression analysis was used to identify the influencing factors.Results:A total of 3 447 participants were included, and the rate of hepatitis B booster vaccination was 32.93% (1 135 participants). Logistic regression analysis showed that the people at the age of 18-27 and 28-34, as well as high school (technical secondary school) education level had high incidence of booster vaccination[ OR(95% CI)=1.485(1.173-1.879), 1.855 (1.362-2.525) and 1.500 (1.234-1.825)]. People who had a history of marriage, lived in city, took examination for hepatitis B actively had high incidence of booster immunization[ OR(95% CI)=1.636(1.277-2.097), 1.390(1.077-1.794) and 1.201 (1.000-1.443)]. People living with family members without hepatitis B had low incidence of booster immunization[ OR(95% CI)=0.255(0.099-0.657)]. People who didn’t know whether they lived with HBV carriers had low incidence of booster immunization[ OR(95% CI)=0.186(0.062-0.552)]. The incidence of booster immunization in people with the score of hepatitis B knowledge ≥16 was lower than that of ≤11 [ OR (95% CI)=1.789 (1.371-2.333)], and in people with the score of risk attitude 9-11 was higher than that of 5-8[ OR(95% CI)=1.472(1.149-1.886)]. Population in monitoring site had a lower incidence rate than those in non-monitoring site[ OR(95% CI)=0.304(0.248-0.372)]. Conclusions:The occurrence of hepatitis B booster vaccination is related to multiple factors. Strengthening the propaganda of hepatitis B and hepatitis B vaccine related knowledge can promote the occurrence of hepatitis B booster vaccination.

Objective:To investigate the sero-epidemiological features of HBV infection among people aged 1-29 years in Hebei province in 2014, so as to provide references for estimating the efficiency of measures on prevention and control of the disease.Methods:In 2014, a stratified two-stage cluster sampling method was used to select the subjects from local residents aged 1-29 years in 8 sites in Hebei province. A questionnaire survey was conducted to obtain basic information, including birth date, age, ethnicity, gender and so on. Blood samples were collected to detect HBV markers and statistical analysis was performed to compare the positive rates of HBsAg, anti-HBs and anti-HBc among different groups.Results:A total of 1 015 subjects aged 1-29 were involved in this survey in 2014. The positive rates of HBsAg, anti-HBs and anti-HBc were 1.08%, 53.50% and 6.60%, respectively. The positive rates of HBsAg, anti-HBs and anti-HBc had statistically significant differences among different age groups (1-4, 5-14 and 15-29 years old) ( χ2=14.43, 59.62 and 43.23, P all<0.01) . The positive rates of anti-HBs were 51.98%, 68.18% and 58.82% in Han, Manchu and other ethnic group, respectively, with statistically significant differences ( χ2=59.62, P<0.05) . For the people born during 2002-2013 when hepatitis B vaccine was integrated in expanded program of immunization (EPI) , the positive rates of HBs, anti-HBsAg and anti-HBc were 0.29%, 57.65% and 3.38%, respectively. And the positive rates of the three serum markers in different age groups were significantly different ( χ2trend=13.12, 14.43 and 52.58, P all<0.05) . There were 8 modes of HBV markers detected, in which single anti-HBs positive mode and negative mode of 5 indicators were the most common ones with the detection rates of 49.06% and 44.34%, respectively. Conclusions:The positive rate of HBsAg is low among people aged 1-29 years in Hebei province, and the HBsAg prevalence has decreased to less than 1% since HBV vaccine was integrated into EPI. It shows that the national EPI strategy for hepatitis B has achieved good effect.

Importance: Whether herd immunity through mass vaccination is sufficient to curb SARS-CoV-2 transmission requires an understanding of the duration of vaccine-induced immunity, and the necessity and timing of booster doses. Objective: To evaluate immune persistence of two priming doses of CoronaVac, and immunogenicity and safety of a third dose in healthy adults [≥]60 years. Design, setting, and participants: We conducted a vaccine booster study built on a single-center, randomized, double-blind phase 1/2 trial of the two-dose schedule of CoronaVac among healthy adults[≥]60 years in Hebei, China. We examined neutralizing antibody titres six months or more after the second dose in all participants. We provided a third dose to 303 participants recruited in phase 2 trial to assess their immune responses. Interventions: Two formulations (3 g, and 6 g) were used in phase 1 trial, and an additional formulation of 1.5 g was used in phase 2 trial. All participants were given two doses 28 days apart and followed up 6 months after the second dose. Participants in phase 2 received a third dose 8 months after the second dose. Main outcomes and measures: Geometric mean titres (GMT) of neutralizing antibodies to live SARS-CoV-2 and adverse events were assessed at multiple time points following vaccination. Results: Neutralizing antibody titres dropped below the seropositive cutoff of 8 at 6 months after the primary vaccination in all vaccine groups in the phase 1/2 trial. A third dose given 8 months or more after the second dose significantly increased neutralizing antibody levels. In the 3 g group (the licensed formulation), GMT increased to 305 [95%CI 215.3-432.0] on day 7 following the third dose, an approximately 7-fold increase compared with the GMT 28 days after the second dose. All solicited adverse reactions reported within 28 days after a booster dose were of grade 1 or 2 severity. Conclusion and relevance: Neutralizing antibody titres declined substantially six months after two doses of CoronaVac among older adults. A booster dose rapidly induces robust immune responses. This evidence could help policymakers determine the necessity and the timing of a booster dose for older adults. Trial registration: ClinicalTrials.gov (NCT04383574).

Background: The COVID-19 vaccine for children and adolescents, who are indispensable populations to curb the pandemic, would protect this population against rare severe COVID-19 and infectious conditions. Here we aimed to assess the safety, tolerability and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents aged 3-17 years old. Methods: We did a randomised, double-blind, placebo-controlled phase 1/2 clinical trial of CoronaVac in healthy children and adolescents aged 3-17 years old in Zanhuang (Hebei, China). Vaccine (in 0 ·5ml aluminum hydroxide adjuvant) or placebo (adjuvant only) was given by intramuscular injection in two doses (day 0 and day 28). We conducted phase 1 trial in 71 participants with an age de-escalation in tree groups and dose-escalation in two blocks (1.5ug or 3ug per injection). Within each block, participants were randomly assigned (3:1) using block randomisation to receive CoronaVac or placebo. In phase 2, participants were randomly assigned (2:2:1) using block randomisation to receive either CoronaVac at 1.5ug or 3ug per dose, or placebo. The primary safety endpoint was adverse reactions within 28 days after each injection in all participants who received at least one dose. The primary immunogenicity endpoint was seroconversion rate at 28 days after the second injection and its GMT as the secondary endpoint. This study is ongoing and is registered with ClinicalTrials.gov (NCT04551547).Findings: Between October 31 and December 2, 2020, 72 participants were enrolled in phase 1, and between December 12 and December 30, 2020, 480 participants were enrolled in phase 2. 500 participants received at least one dose of vaccine or placebo (n=71 for phase 1 and n=479 for phase 2; safety population). In the combined safety profile of phase 1 and phase 2, any adverse reactions within 28 days after injection occurred in 56 (26%) of 219 participants in the 1·5ug group, 63 (29%) of 217 in the 3ug group and 27 (24%) of 114 in the placebo group, without significant difference. Most adverse reactions were mild and moderate in severity and injection site pain (73[13%]) of 550 participants was the most frequently reported event. As of March 12, 2021, only one serious adverse event has been reported, which was considered unrelated to vaccination. In phase 1, seroconversion after the second dose was observed in 27 of 27 participants (100·0% [95%CI 87·3-100·0]) in the 1·5ug groups and 26 of 26 participants (100·0% [86·8-100·0]) in the 3ug group, with the geometric mean titers of 55·0 (95%CI 38·9-77·9) and 117·4 (87·8-157·0). In phase 2, seroconversion was seen in 180 of 186 participants (96·8% [93·1-98·8]) in the 1·5ug group and 180 of 180 participants (100·0% [98·0-100·0]) in the 3ug group, with the geometric mean titers of 86·4 (73·9-101·0) and 142·2 (124·7-162·1). There were no detectable antibody responses in the placebo groups. Interpretation: CoronaVac was well tolerated and induced strong neutralising antibody responses in children and adolescents aged 3-17 years. The study has provided solid safety and immunogenicity data to support the further study and use of CoronaVac in children and adolescents.Trial Registration: NCT04551547Funding Statement: Chinese National Key Research and Development Program and Beijing Science and Technology Program.Declaration of Interests: QG and XL are employees of Sinovac Life Sciences Co., Ltd. YS, WY and LW are employees of Sinovac Biotech Ltd. All other authors declare no competing interests.Ethics Approval Statement: The clinical trial protocol and informed consent form were approved by the Ethics Committee of Hebei CDC (IRB2020-005).

Objective: To assess the immune effect of different types of hepatitis B vaccine (HepB) booster doses 2-32 years after primary immunization, explore the influencing factors, and offer guidance regarding the necessity and timing of boosters. Methods: In total, 1163 participants who were born from 1986 to 2015, received the HepB full-course primary vaccination, were hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) negative, and had hepatitis B surface antibody (anti-HBs) <10 mIU/mL were enrolled. Individuals were randomly divided into two groups and received a booster dose of HepB. Venous blood samples were collected 30 days later and tested for anti-HBs. Results: In total, 595 and 568 individuals received a single dose of HepB (CHO) and HepB (SC), respectively. Venous blood samples were obtained from 1079 vaccinees (CHO: 554, SC: 525). The seroconversion rates were 93.68% (519/554) and 86.67% (455/525) (p < 0.05), with geometric mean concentrations (GMCs) of 426.58 mIU/ml and 223.8 mIU/ml, respectively. This result indicated that BMI, smoking status, vaccine types of booster and prebooster anti-HBs concentration significantly influenced anti-HBs levels. Only BMI, prebooster anti-HBs concentrations and booster types were different between the anti-HBs positive and negative groups. Conclusions: Participants boostered with HepB (CHO) had a relatively higher seroconversion rate than those boostered with HepB (SC). The high seroconversion rates in the two groups suggested that the subjects remained protected despite low circulating antibodies, so there is currently no urgent need for booster immunization. Factors including BMI > 25 and prebooster anti-HBs concentration <2.5 mIU/mL, which contributed to lower responses to a booster dose, might indicate a greater risk of breakthrough infection. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

Objective: Aanalysis the effect of booster one dose of hepatitis B vaccine after 21-32 years of primary immunization in Zhengding Country of Hebei Province. Methods: A total of 322 participants who were born between 1986 and 1996, received a full course of primary vaccination with plasma-derived hepatitis B vaccine (HepB), had no experience with booster vaccination, were HBsAg, anti-HBcnegative, had anti-HBs<10 mIU/ml, completed the booster and had laboratory results were enrolled between August 2017 to February 2018. A simple random method was uesd to randomly assigned 322 subjects to two groups, receiving a booster dose of HepB derived from either Saccharomyces cerevisiae ［HepB (SC), (151 cases)］ or Chinese hamster ovary-derived HepB ［HepB (CHO), (171 cases)］, the dose was 20 μg. Blood samples were collected 30 days after boosting and quantitatively tested for the geometric mean concentration (GMC) of anti-HBs to assess immunological effect. The related influencing factors of GMC and seroconversion rates of anti-HBs were analyzed by multiple linear regression and multivariate logistic regression models. Results: The 266 subjects (82.61%) had anti-HBs≥ 10 mIU/ml, and GMC was (131.63±12.94) mIU/ml.The seroconversion rates of anti-HBs in the anti-HBs<2.5 mIU/ml group and 2.5-10 mIU/ml group were 74.54% (161 cases) and 99.06% (105 cases), respectively (P<0.001).The seroconversion rates of anti-HBs after one dose of HepB (CHO) was higher than that of one dose of HepB (SC), the seroconversion rates were 87.13% (149 cases) and 77.48% (117 cases), respectively (P=0.023). Participants boostered with HepB (CHO) was the factor influencing the effect of strengthening immunization compared with boostered with HepB (SC), and OR (95%CI) was 1.91 (1.02-3.56) (P=0.042).Compared with anti-HBs<2.5 mIU/ml, prebooster anti-HBs was between 2.5 mIU/ml and 10 mIU/ml was the related factor of seroconversion rates of anti-HBs after booster immunization, and OR (95%CI) was 36.15 (4.91-266.02) (P<0.001). Conclusion: Participants boostered withone dose of HepB had a good immune response. Pre-booster anti-HBs concentration and a variety of vaccine were related factors of immune response.

To assess the immune persistence conferred by a Chinese hamster ovary (CHO)-derived hepatitis B vaccine (HepB) 17 to 20 years after primary immunization during early life. Participants born between 1997 and 1999 who received a full course of primary vaccination with HepB (CHO) and who had no experience with booster vaccination were enrolled. Blood samples were required from each participant for measurement of hepatitis B surface antibody (anti-HBs), surface antigen and core antibody levels. For those who possessed an anti-HBs antibody < 10 mIU/mL, a single dose of HepB was administered, and 30 days later, serum specimens were collected to assess the booster effects. A total of 1352 participants were included in this study. Of these, 1007 (74.5%) participants could retain an anti-HBs antibody ≥10 mIU/mL, with a geometric mean concentration (GMC) of 57.4 mIU/mL. HBsAg was detected in six participants, resulting in a HBsAg carrier rate of 0.4% (6/1352). Of those participants with anti-HBs antibodies < 10 mIU/mL, after a challenge dose, 231 (93.1%) presented an anti-HBs antibody ≥10 mIU/mL, with a GMC of 368.7 mIU/mL. A significant increase in the anti-HBs positive rate (≥ 10 mIU/mL) after challenge was observed in participants with anti-HBs antibodies between 2.5 and 10 mIU/mL and participants boosted with HepB (CHO), rather than those with anti-HBs antibodies < 2.5 mIU/mL and those boosted with HepB (SC). Since satisfactory immune protection against HBV infection conferred by primary vaccination administered 17–20 years ago was demonstrated, there is currently no urgent need for booster immunization.

目的 了解河北省成年人群乙肝疫苗接种情况,分析影响乙肝疫苗接种的因素,为乙肝的预防控制提供参考依据.方法 运用多阶段整群系统随机抽样方法,抽取河北省22个县区内的18～60岁常驻居民进行面对面问卷调查.运用单因素分析和多因素logistic回归模型分析影响乙肝疫苗接种率的主要因素.结果 河北省成年人乙肝疫苗接种率为14.70％ (390/2 653).多因素logistic回归分析显示,调查对象的年龄、职业、居住地、文化程度以及暴露于有偿献血、针灸治疗、长期与乙肝表面抗原(HBsAg)阳性成员一起生活是影响成年人乙肝疫苗接种的因素.结论 河北省成年人群乙肝疫苗接种率低,应着重对成年人中较高年龄人群、农民以及高危人群实施科学的乙肝疫苗接种知识的宣传教育.

目的了解单采血浆还输血球的有偿献血20年后,河北省某＂献血村＂人群乙型病毒性肝炎（乙肝）的流行现状,探讨乙肝传播的危险因素,为预防控制乙肝在该人群传播提供参考。方法以河北省某＂献血村＂常住村民为研究对象,进行问卷调查、采集静脉血,利用酶联免疫吸附试验检测乙肝病毒（Hepatitis B Virus,HBV）血清学标志物,采用统计分析系统9.2软件对数据进行统计分析。结果河北省某＂献血村＂人群乙肝病毒表面抗原（HBV Surface Antigen,HBs Ag）和抗乙肝病毒核心抗原抗体（Antibody to HBV Core Antigen,Anti-HBc）流行率分别为4.46%（22/493）和33.87%（167/493）,均接近河北省自然人群水平。母婴传播是导致HBs Ag阳性的主要因素[母亲HBs Ag阳性组vs阴性组：比值比（Odds Ratio,OR）=13.177,95%可信区间（Confidence Interval,CI）：2.457-70.669];接种乙肝疫苗（Hepatitis B Vaccine,Hep B）是Anti-HBc阳性的保护因素（接种组vs未接种组：OR=0.014,95%CI：0.003-0.058）。结论 HBV在河北省某＂献血村＂人群主要通过母婴传播。目前预防控制乙肝的策略应放在发现HBs Ag阳性的孕产妇,阻断母婴传播,以及提高成年人群Hep B的接种率。

目的 了解单采血浆还输血球的有偿献血20年后,河北省某"献血村"人群乙型病毒性肝炎(乙肝)的流行现状,探讨乙肝传播的危险因素,为预防控制乙肝在该人群传播提供参考.方法 以河北省某"献血村"常住村民为研究对象,进行问卷调查、采集静脉血,利用酶联免疫吸附试验检测乙肝病毒(Hepatitis B Virus,HBV)血清学标志物,采用统计分析系统9.2软件对数据进行统计分析.结果 河北省某"献血村"人群乙肝病毒表面抗原(HBV SurfaceAntigen,HBsAg)和抗乙肝病毒核心抗原抗体(Antibody to HBV Core Antigen,Anti-HBc)流行率分别为4.46％(22/493)和33.87％ (167/493),均接近河北省自然人群水平.母婴传播是导致HBsAg阳性的主要因素[母亲HB-sAg阳性组vs阴性组:比值比(Odds Ratio,OR)=13.177,95％可信区间(Confidence Interval,CI):2.457～70.669];接种乙肝疫苗(Hepatitis B Vaccine,HepB)是Anti-HBc阳性的保护因素(接种组vs未接种组:OR =0.014,95％ CI:0.003～0.058).结论 HBV在河北省某"献血村"人群主要通过母婴传播.目前预防控制乙肝的策略应放在发现HBsAg阳性的孕产妇,阻断母婴传播,以及提高成年人群HepB的接种率.